The IRA And US FDA: How Will Agency View Any Drug Development Changes?
Executive Summary
US biopharma companies are warning of significant changes in drug development priorities as they prepare for the implementation of new Medicare pricing measures enacted in 2022. Those changes will have ripple effects on the FDA, which may spark some responses.
You may also be interested in...
Medicare Drug Pricing Casts A Cloud Over J.P. Morgan’s Opening Day
Inflation Reduction Act means that industry ‘will have to adjust’ to new market realities, especially for small molecule drugs.
An Ex-Commissioner’s Bleak Take On The State Of Biopharma Innovation
Former US FDA Commissioner Robert Califf remains eager to encourage broader use of real-world evidence – but his blunt, pessimistic read on the state of biopharma innovation is remarkable coming from a former FDA head.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.